Inflammation as Therapeutic Objective in Stroke
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Ischemic stroke is the most frequent cause of persistent neurologic disability in modern Western societies. Albeit it is still not clear whether inflammation is merely an epiphenomenon or rather has a disease-promoting function, accumulating evidence implicates inflammation in many forms of acute neurodegenerative disorders including ischemia. The immune cell influx during a neuropathological event is thought to be elicited by glial cells, especially microglia. This article reviews the cellular and molecular pathways involved in stroke-induced inflammatory response in the CNS. We focused on how CNS innate immune cells including microglia and macrophages play integral roles in receiving and propagating inflammatory signals, and how activated microglia secrete a wide range of factors. We present the relevance of the expression of adhesion molecules after ischemia including selectin, immunoglobulin superfamily, integrins, and the role of inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases. Further, we explore the role of transcription factors in inflammation, and the function of immunomodulation and innate and adaptive immunity in brain ischemia, focusing on immunosupression therapies for acute stroke. Although several approaches for anti-inflammatory treatment have proven effective in animal models, clinical trials of immune system modulation therapy after stroke have not yet proved successful. There is still much to be done in order to translate interesting findings into therapies, but undoubtedly studying the cellular and molecular pathways may not only improve our understanding of inflammatory mechanism but also serve as a basis for designing effective therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630 · cited 1×
“Stroke is the second leading cause of death and the burden of disease in high income countries [1].”
BackgroundToll-like receptors in innate immunity
Takeda, K. (2004) · International Immunology · doi:10.1093/intimm/dxh186 · Cited by 3,328 · cited 1×
“TLRs also detect endogenous ligands that might signal other dangerous conditions, such as the presence of degradation products from macromolecules, products from proteolytic cascades, intracellular components of broken cells and products from genes that are activated by inflammation, such as hyaluronan, fibrinogen, fi…”
BackgroundPerivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo
Hickey, W. F., & Kimura, H. (1988) · Science · doi:10.1126/science.3276004 · Cited by 1,466 · cited 1×
“In the adult, parenchymal microglia in contrast to perivascular “microglia” are not frequently repopulated by fresh monocytes [10].”
BackgroundSchindler, R., Mancilla, J., Endres, S., Ghorbani, R., Clark, S., & Dinarello, C. (1990) · Blood · doi:10.1182/blood.v75.1.40.40 · Cited by 1,012
Tumor Necrosis Factor-α: A Mediator of Focal Ischemic Brain Injury
Barone, F. C., Arvin, B., White, R. F., Miller, A., Webb, C. L., Willette, R. N., Lysko, P. G., & Feuerstein, G. Z. (1997) · Stroke · doi:10.1161/01.str.28.6.1233 · Cited by 863
Tilg, H., Trehu, E., Atkins, M., Dinarello, C., & Mier, J. (1994) · Blood · doi:10.1182/blood.v83.1.113.113 · Cited by 817
The impact of systemic infection on the progression of neurodegenerative disease
Perry, V. H., Newman, T. A., & Cunningham, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1032 · Cited by 428 · cited 1×
“Aging or neurological disease, however, may provide a brain environment where microglia are more “reactive or primed” to a peripheral immune challenge [13].”
BackgroundMicroglia: activation and their significance in the central nervous system
Nakajima, K., & Kohsaka, S. (2001) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a002969 · Cited by 371
The many faces of tumor necrosis factor in stroke
Hallenbeck, J. M. (2002) · Nature Medicine · doi:10.1038/nm1202-1363 · Cited by 367
Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury
Soriano, S. G., Amaravadi, L. S., Wang, Y. F., Zhou, H., Yu, G. X., Tonra, J. R., Fairchild-Huntress, V., Fang, Q., Dunmore, J. H., Huszar, D., et al. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00033-4 · Cited by 222 · cited 1×
“After transient focal cerebral ischemia, fractalkinedeficient mice had a reduction in infarction size and lower mortality rate, when compared to wild-type littermates [126].”
Cited by
Caspase signalling controls microglia activation and neurotoxicity
Burguillos, M. A., Deierborg, T., Kavanagh, E., Persson, A., Hajji, N., Garcia-Quintanilla, A., Cano, J., Brundin, P., Englund, E., Venero, J. L., et al. (2011) · Nature · doi:10.1038/nature09788 · Cited by 585
An Inflammation-Centric View of Neurological Disease: Beyond the Neuron
Skaper, S. D., Facci, L., Zusso, M., & Giusti, P. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00072 · Cited by 457
Microglial Activation in Stroke: Therapeutic Targets
Yenari, M. A., Kauppinen, T. M., & Swanson, R. A. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.07.005 · Cited by 389
“Control” laboratory rodents are metabolically morbid: Why it matters
Martin, B., Ji, S., Maudsley, S., & Mattson, M. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912955107 · Cited by 354
“Thus, drugs such as glutamate receptor antagonists (71) and antiinflammatory agents (72) may be effective in animal models, but ineffective in human clinical trials, because they modify processes associated with a sedentary gluttonous lifestyle instead of, or in addition to, stroke-specific processes.”
BackgroundHerz, J., Reitmeir, R., Hagen, S. I., Reinboth, B. S., Guo, Z., Zechariah, A., ElAli, A., Doeppner, T. R., Bacigaluppi, M., Pluchino, S., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.026 · Cited by 62
Metadata
- Authors
- Jordan, J., Segura, T., Brea, D., Galindo, M., & Castillo, J.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-11-01
- Volume
- 14
- Issue
- 33
- Pages
- 3549-3564
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2112288393
- Cited by
- 84
- References
- 12
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inflammation as Therapeutic Objective in Stroke. https://app.cochat.ai/papers/10.2174/138161208786848766
- The paper
- Jordan, J., Segura, T., Brea, D., Galindo, M., & Castillo, J. (2008). Inflammation as Therapeutic Objective in Stroke. Current Pharmaceutical Design. https://doi.org/10.2174/138161208786848766
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.